David Middleman
David develops and advances large-scale litigation to hold corporations accountable for widespread harm.
David develops and advances large-scale litigation to hold corporations accountable for widespread harm.
During the past three decades, David Middleman has built and advanced large-scale litigation on behalf of people harmed by defective pharmaceutical products, medical devices, toxic exposures, and other corporate misconduct. With a focus on identifying emerging cases and further strengthening DiCello Levitt’s mass tort capabilities, he helps position the firm at the forefront of high-impact litigation against some of the world’s largest corporations.
David has represented plaintiffs in all 50 states in matters involving catastrophic personal injury, wrongful death, commercial automobile and trucking accidents, product liability, toxic torts, premises liability, and claims against multinational pharmaceutical and health care companies.
David is widely recognized for developing a scalable approach to mass tort litigation, combining national client outreach, strategic partnerships, and disciplined case development to efficiently build and support high-volume dockets. He co-founded Pulaski & Middleman, a firm dedicated almost exclusively to pharmaceutical and medical device litigation, where he helped develop and manage tens of thousands of claims nationwide and contributed to recoveries totaling billions of dollars. Earlier in his career, he co-founded Middleman Levin, launching the firm immediately after law school and growing its practice through innovative client engagement strategies.
At DiCello Levitt, David leverages this experience to help drive the firm’s mass tort efforts from the earliest stages of case development through resolution. His work draws on a deep network within the plaintiffs’ bar and a longstanding ability to evaluate claims, structure litigation strategies, and scale complex matters efficiently. He also brings experience advising on litigation finance and case valuation, including work on large-scale portfolios and bankruptcy-related matters.
Throughout his career, David has remained focused on ensuring that individuals harmed by corporate misconduct have meaningful access to justice, particularly in cases where the scale and complexity of the litigation would otherwise put relief out of reach.
